Clinical interests: Dr. Smith's clinical focus is on lung injury prevention in preterm and term neonates. She works clinically on strategies to minimize lung trauma in infants requiring ventilation due to respiratory failure in the neonatal period.

Scholarly Focus: Dr. Smith is the site Principal Investigator at Seattle Children’s Hospital for the industry‐ sponsored trial by United Therapeutics entitled “Intravenous Remodulin (Treprostinil) as Add‐on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo‐ Controlled, Safety and Efficacy Study.” She is also working on a hospital‐based study entitled “Liquid Assisted Ventilation for Lung Recruitment and Protection in Patients with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support” which is funded by private monies from the Ladybug Foundation. To promote improved care for infants while on transport she works with others in the Division on telemedicine for our transport services and referral sites.

Research Funding:

2016 ‐ current Intravenous Remodulin (Treprostinil) as Add‐on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo‐Controlled, Safety and Efficacy Study.” Role: Site PI, Total award $113,713

2018 ‐ current Liquid Assisted Ventilation for Lung Recruitment and Protection in Patients with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support. Role: PI, Total award:

$98,798

Administration/Education Roles: Dr. Smith is involved in the Extracorporeal Life Support (ECLS) Program at Seattle Children’s Hospital and serves on the Steering Committee, which focuses on improving techniques to maximally support newborn infants not responsive to conventional therapies. She also serves as the Manager of Divisional Respiratory Care Programs with the goal of promoting improved ventilation strategies for neonates requiring ventilatory support in our region and provides teaching throughout the year on ventilation in the sick newborn, as well as pulmonary hypertension and ECLS for residents, fellows, advanced practice providers, nurses and respiratory therapists.